EUVIMEDEUVIMED entdecken
Multizentrische StudieValidierungsstudie

Validation of MELD 3.0 in patients with alcoholic liver cirrhosis using prospective KACLiF cohort

Jihye Lim iD, Jung Hee Kim iD, Sung-Eun Kim, Seul Ki Han, Tae Hyung Kim, Hyung Joon Yim iD, Young Kul Jung, Do Seon Song iD, Eileen L Yoon, Hee Yeon Kim, Seong Hee Kang, Young Chang und 13 weitere

Journal of Gastroenterology and Hepatology · 2024

DOI: 10.1111/jgh.16591 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Jihye Lim und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic Universi…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Alcoholic, Severity of Illness Index, End Stage Liver Disease. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim The Model for End‐Stage Liver Disease (MELD) is a reliable prognostic tool for short‐term outcome prediction in patients with end‐stage liver disease. MELD 3.0 was introduced to enhance the predictive accuracy. This study assessed the performance of MELD 3.0, in comparison to MELD and MELD‐Na, in patients with alcoholic liver cirrhosis.

Methods

This multicenter prospective cohort study comprised patients with alcoholic cirrhosis admitted for acute deterioration of liver function in the Republic of Korea between 2015 and 2019. This study compared the predictive abilities of MELD, MELD‐Na, and MELD 3.0, for 30‐day and 90‐day outcomes, specifically death or liver transplantation, and explored the factors influencing these outcomes.

Results

A total of 1096 patients were included in the study, with a mean age of 53.3 ± 10.4 years, and 82.0% were male. The mean scores for MELD, MELD‐Na, and MELD 3.0 at the time of admission were 18.7 ± 7.2, 20.6 ± 7.7, and 21.0 ± 7.8, respectively. At 30 and 90 days, 7.2% and 14.1% of patients experienced mortality or liver transplantation. The areas under the receiver operating characteristic curves for MELD, MELD‐Na, and MELD 3.0 at 30 days were 0.823, 0.820, and 0.828; and at 90 days were 0.765, 0.772, and 0.776, respectively. Factors associated with the 90‐day outcome included concomitant chronic viral hepatitis, prolonged prothrombin time, elevated levels of aspartate transaminase, bilirubin, and creatinine, and low albumin levels.

Conclusion

MELD 3.0 demonstrated improved performance compared to previous models, although the differences were not statistically significant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver Cirrhosis, AlcoholicSeverity of Illness IndexEnd Stage Liver DiseaseHumansMaleFemaleMiddle AgedProspective StudiesPrognosisLiver TransplantationAdultCohort StudiesROC CurvePredictive Value of TestsRepublic of KoreaTime Factors

Stichwörter der Autor:innen

acutealcoholicend‐stage liver diseaseliver cirrhosisliver failureliver transplantation

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hallym Medical Center, Hallym University College of Medicine, Chuncheon, Republic of Korea.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.
  • Division of Gastroenterology, Department of Internal Medicine, Korea University Medical Center, Seoul, Republic of Korea.
  • Division of Gastroenterology and Hepatology Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Jihye Lim, Jung Hee Kim, Hyung Joon Yim, Do Seon Song, Jeong-Ju Yoo, Moon Young Kim, Sang Gyune Kim, Won Kim

Zitieren

APA

Lim, J., Kim, J. H., Kim, S. E., Han, S. K., Kim, T. H., Yim, H. J., Jung, Y. K., Song, D. S., Yoon, E. L., Kim, H. Y., Kang, S. H., Chang, Y., Yoo, J. J., Lee, S. W., Park, J. G., Park, J. W., Jeong, S. W., Suk, K. T., Kim, M. Y., …, & Korean Acute on‐Chronic Liver Failure (KACLiF) Study Group (2024). Validation of MELD 3.0 in patients with alcoholic liver cirrhosis using prospective KACLiF cohort. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16591

Vancouver

Lim J, Kim JH, Kim SE, Han SK, Kim TH, Yim HJ, et al. Validation of MELD 3.0 in patients with alcoholic liver cirrhosis using prospective KACLiF cohort. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16591

BibTeX
@article{Lim2024,
  author = {Lim, Jihye and Kim, Jung Hee and Kim, Sung-Eun and Han, Seul Ki and Kim, Tae Hyung and Yim, Hyung Joon and Jung, Young Kul and Song, Do Seon and Yoon, Eileen L and Kim, Hee Yeon and Kang, Seong Hee and Chang, Young and Yoo, Jeong-Ju and Lee, Sung Won and Park, Jung Gil and Park, Ji Won and Jeong, Soung Won and Suk, Ki Tae and Kim, Moon Young and Kim, Sang Gyune and Kim, Won and Jang, Jae Young and Yang, Jin Mo and Kim, Dong Joon and Korean Acute on‐Chronic Liver Failure (KACLiF) Study Group, Korean Acute on‐Chronic Liver Failure (KACLiF) Study Group},
  title = {Validation of MELD 3.0 in patients with alcoholic liver cirrhosis using prospective KACLiF cohort},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2024},
  doi = {10.1111/jgh.16591}
}
Kostenlos starten →